Skip to content
Search

Latest Stories

Dozens of 'protected' pharmacies closing despite support scheme- NPA analysis reveals

At least 58 of the specially protected pharmacies have closed in the past two years despite
'Closed' shop sign (gettyimages)

Over 1,250 pharmacies in England have been forced to close in the past decade, leaving some areas at risk of becoming pharmacy deserts 

A new analysis by the National Pharmacy Association (NPA) has highlighted the alarming closure of dozens of pharmacies identified by the government as vital to their communities.

Dozens of specially protected pharmacies have closed in the past two years despite their inclusion in the Pharmacy Access Scheme (PhAS).


The scheme, revised in January 2022, is designed to “capture the pharmacies that are most important for patient access, those pharmacies where patient and public access would be affected should they close.”

Eligible pharmacies—those located more than one mile from the nearest alternative or in deprived areas—were provided additional funding to ensure public access to NHS community pharmaceutical services.

The scheme, part of the Community Pharmacy Contractual Framework (CPCF), was allocated up to £20 million.

However, the NPA’s review of the General Pharmaceutical Council’s (GPhC) current national register of pharmacies shows that at least 58 pharmacies listed under PhAS in 2022 have since closed.

These closures reflect the broader strain on the pharmacy network, which has been shrinking due to a decade’s budget cuts.

NPA chair Nick Kaye expressed deep concern over the findings: “It’s horrifying that so many of the pharmacies singled out by the government as in need of special support to protect their communities are now shut for good.

“This analysis just shows the potentially devastating impact on patients if they lose their local pharmacy to chronic underfunding that has cut a swathe through local health services in the past 10 years.

“Pharmacies are a haven of invaluable health advice, medicine supplies and local expertise upon which millions of people rely but are still closing at an alarming rate.”

He called on the government to provide emergency funding to halt the closures and unleash the power of the pharmacy network to drive care in the communities, noting that the findings are “still more evidence that they need to act now.”

Among the pharmacies that have shut under the scheme are:

  • Bishop’s Lydeard Pharmacy, Somerset: Patients now face a four-mile journey or a 30-minute bus ride to access the nearest alternative pharmacy. The pharmacy previously served several nearby villages.
  • Wheaton Aston Pharmacy, Stafford: Patients must now travel nearly six miles to reach another pharmacy, with the closure impacting nearby villages as well.

Over the past decade, more than 1,250 pharmacies in England have been forced to close, according to the NPA.

The association has warned that this trend risks creating “pharmacy deserts” in some areas, potentially leaving patients with long distances to travel for vital medication or advice.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less